Background And Purpose: Progressive multifocal leukoencephalopathy (PML) is caused by reactivation of JC virus (JCV) infection due to combined host and viral factors. Anti-JCV antibodies provide a means to assess JCV exposure and stratify PML risk. The reported seroprevalence of anti-JCV antibodies varies from 39% to 91% depending on assay methodology and population studied. A two-step anti-JCV antibody assay (STRATIFY JCV™; Focus Diagnostics, Cypress, CA, USA) detected anti-JCV antibodies in approximately 55% of multiple sclerosis (MS) patients. This study describes the prevalence of anti-JCV antibodies in a large, multinational MS population.
Methods: This cross-sectional epidemiology study was designed to enroll a minimum of 2000 patients with an MS diagnosis of any type, irrespective of treatment, from Europe, Canada and Australia. Anti-JCV antibody prevalence was determined by STRATIFY JCV; the effects of demographic and disease characteristics were evaluated.
Results: A total of 7724 patients from 10 countries participated in the study. Overall anti-JCV antibody prevalence was 57.1% (95% confidence interval 56.0%-58.2%). Seroprevalence was significantly associated with increasing age, gender and country of current residence (P < 0.0001). No significant differences in anti-JCV antibody prevalence were associated with MS disease characteristics, including duration and type of MS and number and duration of MS therapies.
Conclusions: Overall seroprevalence of anti-JCV antibodies in MS patients from Europe, Canada and Australia was consistent with previous studies using the STRATIFY JCV assay. Anti-JCV prevalence differed significantly by age, gender and country, but no geographical pattern was evident. Disease and treatment type were not associated with differences in anti-JCV antibody status.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ene.12304 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-JCV antibody index seroconversion in Turkish multiple sclerosis patients treated with natalizumab.
Neurol Sci
December 2024
Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Background: The anti-JCV antibody index is widely used to monitor multiple sclerosis (MS) patients receiving natalizumab, as seroconversion is linked to an increased risk of progressive multifocal leukoencephalopathy. This study aimed to evaluate the prevalence and risk factors of anti-JCV antibody seroconversion in patients treated with natalizumab.
Methods: We included MS patients exposed to natalizumab treatment for at least one year, with a negative anti-JCV antibody index at baseline, and a minimum of two anti-JCV antibody assessments more than six months apart.
Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice.
Mult Scler
November 2024
Department of Neurology, Center of Clinical Neuroscience, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.
Ocrelizumab-induced organizing pneumonia in multiple sclerosis: case report and literature review.
Arch Clin Cases
July 2024
Division of Intensive Care Medicine and Pulmonary Medicine, Northwell Health, Port Jefferson, NY, USA.
Patients with relapsing-remitting multiple sclerosis should be offered disease-modifying therapies as part of their management. Recommended options include integrin antagonist therapy including natalizumab as well as anti-CD20 monoclonal antibodies like, ocrelizumab, rituximab, ofatumumab, and ublituximab. These therapies reduce relapse rates and slow brain lesion accumulation.
View Article and Find Full Text PDFAssociation of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
J Neurol Sci
June 2024
First Department of Neurology, School of Medicine, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Introduction: Progressive multifocal leukoencephalopathy (PML) is a potentially life-threatening complication among Multiple Sclerosis (MS) patients under natalizumab treatment, with serum anti-JCV antibody titers being used for stratification risk. Given the critical role of interferon (IFN)/B-cell activating factor (BAFF) axis in humoral immune responses against viruses, we explored whether it is involved in the generation of serum anti-JCV antibodies among these patients.
Methods: 162 consecutive patients with relapsing-remitting MS under natalizumab treatment were included.
Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
Mult Scler Relat Disord
July 2024
Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Electronic address:
Article Synopsis
- - Natalizumab is a treatment for relapsing multiple sclerosis (MS) but increases the risk of a serious brain infection called progressive multifocal leukoencephalopathy (PML), and researchers explored if detecting JCV-DNA in stool could help assess this risk.
- - A study of 30 MS patients on natalizumab found JCV-DNA in urine samples of four patients but none in stool or blood, and all viral isolates were of the wild-type without variants associated with PML.
- - The study concluded that stool samples are not useful for assessing PML risk, suggesting that further research is necessary to understand where harmful JCV variants come from.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!